Delta-Fly Pharma,Inc.
| Market Cap | 2.6B |
| P/E Ratio | - |
| P/B Ratio | 12.54 |
| EPS | -195.58 |
| Dividend Yield | - |
| D/E Ratio | 0.56 |
| Current Ratio | 2.52 |
| Market Segment | Growth |
| Accounting | Japan GAAP |
| Currency | JPY |
Business Overview
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase 1/2 clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer. The company was incorporated in 2010 and is headquartered in Tokushima, Japan.
Key Financial Metrics
Profitability
Returns & Efficiency
Financial Health
| Industry | PHARMACEUTICAL |
| Market Segment | Growth |
| Accounting | Japan GAAP |
| Currency | JPY |
| Fiscal Year | 2025 |
Stock Chart
Full charting with technical indicators, candlestick, line charts, and more.
Company Profile
| Company Name | Delta-Fly Pharma,Inc. |
| Ticker | 4598 |
| Exchange | TSE |
| Sector | Pharmaceutical |
| Industry | PHARMACEUTICAL |
| Market Segment | Growth |
| Accounting | Japan GAAP |
| Fiscal Year | 2025 |
| Currency | JPY |
| Market Cap | 2.6B |
| Revenue | - |
| Net Income | -1.7B |
| P/E Ratio | - |
| EPS | -195.58 |
| Net Margin | - |
| ROE | -6.2% |
| Dividend Yield | - |
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase 1/2 clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer. The company was incorporated in 2010 and is headquartered in Tokushima, Japan.